[HTML][HTML] Clinical outcome predictors for metastatic renal cell carcinoma: a retrospective multicenter real-life case series
M Rizzo, G Pezzicoli, V Tibollo, A Premoli, S Quaglini - BMC cancer, 2024 - Springer
Over the last decades, the therapeutic armamentarium of metastatic renal cell carcinoma
(mRCC) has been revolutionized by the advent of tyrosin-kinase inhibitors (TKI), immune …
(mRCC) has been revolutionized by the advent of tyrosin-kinase inhibitors (TKI), immune …
[HTML][HTML] Mathematical and Machine Learning Models of Renal Cell Carcinoma: A Review
This review explores the multifaceted landscape of renal cell carcinoma (RCC) by delving
into both mechanistic and machine learning models. While machine learning models …
into both mechanistic and machine learning models. While machine learning models …
Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of “palateau”
SE Rebuzzi, G Fornarini, A Signori… - Human Vaccines & …, 2024 - Taylor & Francis
The first-line therapy of metastatic renal cell carcinoma (mRCC) has revolutionized with the
approval of immune checkpoint inhibitors (ICIs) in combination with or without tyrosine …
approval of immune checkpoint inhibitors (ICIs) in combination with or without tyrosine …
[HTML][HTML] Exploring the prognostic implications of cuproptosis-associated alterations in clear cell renal cell carcinoma via in vitro experiments
Z Xing, L Cui, Y Feng, Y Yang, X He - Scientific Reports, 2024 - nature.com
This study investigated the impact of novel copper ionophores on the prognosis of clear cell
renal cell carcinoma (ccRCC) and the tumor microenvironment (TME). The differential …
renal cell carcinoma (ccRCC) and the tumor microenvironment (TME). The differential …
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de‐differentiation (ARON‐1 study)
C Ciccarese, T Büttner, L Cerbone… - … Journal of Cancer, 2024 - Wiley Online Library
Metastatic renal cell carcinoma (mRCC) carrying sarcomatoid features (sRCC) has
aggressive biology and poor prognosis. First‐line immunotherapy (IO)‐based combinations …
aggressive biology and poor prognosis. First‐line immunotherapy (IO)‐based combinations …
[HTML][HTML] Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care
SM Tu, AK Trikannad, S Vellanki, M Hussain, N Malik… - Cancers, 2024 - mdpi.com
Simple Summary The premise that certain checkpoint inhibitors are effective anti-cancer
treatments beyond their immune modulatory capabilities influences current cancer research …
treatments beyond their immune modulatory capabilities influences current cancer research …
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab
A Damassi, M Cremante, A Signori, SE Rebuzzi… - …, 2024 - Taylor & Francis
Aim: To define the prognostic significance of first-line TKI in mRCC patients receiving
nivolumab. Materials and methods: A total of 571 mRCC patients who received≥ second …
nivolumab. Materials and methods: A total of 571 mRCC patients who received≥ second …
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study
F Massari, V Mollica, O Fiala, U De Giorgi… - European Urology …, 2024 - Elsevier
Background and objective Papillary renal cell carcinoma (pRCC) is the most frequent
histological subtype of non-clear cell RCC (nccRCC). Owing to the heterogeneity of …
histological subtype of non-clear cell RCC (nccRCC). Owing to the heterogeneity of …
[HTML][HTML] Comparative analysis of dual immune checkpoint inhibitor combination therapy versus immune checkpoint inhibitor plus tyrosine kinase inhibitor combination …
K Yoshida, N Nagasaka, T Kondo, Y Kobari… - International Journal of …, 2024 - Springer
Background Whether immune checkpoint inhibitor (ICI) plus ICI combination therapy or ICI
plus tyrosine kinase inhibitor (TKI) combination therapy is useful for renal cell carcinoma …
plus tyrosine kinase inhibitor (TKI) combination therapy is useful for renal cell carcinoma …
First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety
T Yanagisawa, K Mori, T Kawada, S Katayama… - … Oncology: Seminars and …, 2024 - Elsevier
Purpose Immune checkpoint inhibitor (ICI)-based combination therapy is a standard
systemic treatment for metastatic renal cell carcinoma (mRCC). Although differential …
systemic treatment for metastatic renal cell carcinoma (mRCC). Although differential …